Progress on therapeutic mRNA vaccines for cancer
- 1Department of Pharmacy, Hubei Provincial Hospital of Traditional Chinese Medicine , ,
- 2Independent Researcher , ,
Abstract
Therapeutic mRNA vaccines are a clinically validated cancer immunotherapy platform using in vitro transcribed mRNA encoding tumor antigens to induce durable anti-tumor immunity. Advances in mRNA engineering, lipid nanoparticle (LNP) delivery, and immunomodulatory combinations have propelled this approach from preclinical models to randomized trials with survival benefit. This review systematically examines vaccine efficacy through an antigen–delivery–immunomodulation tripartite framework. We trace the evolution from shared tumor-associated antigens to personalized neoantigens identified by computational pipelines, discuss ionizable lipid chemistry and LNP formulation for controlled tissue tropism and transfection, and analyze the bidirectional crosstalk between vaccine components and innate immune sensing that shapes adaptive T cell responses. Clinical evidence across melanoma, pancreatic cancer, non-small cell lung cancer, and other solid tumors is critically evaluated, alongside combination strategies—checkpoint blockade, oncolytic virotherapy, and adoptive cell therapy to overcome TME resistance. Persistent challenges include optimal neoantigen selection, standardized immune monitoring, and predictive biomarkers. We conclude that future research should prioritize systematic optimization of the tripartite design through multi-antigen targeting, tissue-specific delivery engineering, and rational combination immunotherapy, aiming to establish mRNA cancer vaccines as a standard-of-care modality.
Related
- 860 mRNA-LNP-mediated immunomodulation for precision cancer vaccines and immunotherapy
- From prophylactic mRNA vaccines against viral infections to therapeutic applications: regulatory science considerations for expanding mRNA platforms
- Promises and pitfalls of mRNA-based vaccines as cancer treatment.
- Dendritic cell-based vaccines for colorectal cancer: Mechanisms, clinical progress and future directions (Review)
- Therapeutic cancer vaccines: development, challenges, and future perspectives
BibTeX
@article{wu2026progress,
title = {{Progress on therapeutic mRNA vaccines for cancer}},
author = {Siyu Wu and Huarong Liao and Wei Zhang},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1980190},
url = {https://europepmc.org/article/PMC/PMC13691540},
note = {CC BY},
}
RIS
TY - JOUR
TI - Progress on therapeutic mRNA vaccines for cancer
AU - Siyu Wu
AU - Huarong Liao
AU - Wei Zhang
PY - 2026
DA - 2026/10/09
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1980190
UR - https://europepmc.org/article/PMC/PMC13691540
AB - Therapeutic mRNA vaccines are a clinically validated cancer immunotherapy platform using in vitro transcribed mRNA encoding tumor antigens to induce durable anti-tumor immunity. Advances in mRNA engineering, lipid nanoparticle (LNP) delivery, and immunomodulatory combinations have propelled this approach from preclinical models to randomized trials with survival benefit. This review systematically examines vaccine efficacy through an antigen–delivery–immunomodulation tripartite framework. We trace the evolution from shared tumor-associated antigens to personalized neoantigens identified by computational pipelines, discuss ionizable lipid chemistry and LNP formulation for controlled tissue tropism and transfection, and analyze the bidirectional crosstalk between vaccine components and innate immune sensing that shapes adaptive T cell responses. Clinical evidence across melanoma, pancreatic cancer, non-small cell lung cancer, and other solid tumors is critically evaluated, alongside combination strategies—checkpoint blockade, oncolytic virotherapy, and adoptive cell therapy to overcome TME resistance. Persistent challenges include optimal neoantigen selection, standardized immune monitoring, and predictive biomarkers. We conclude that future research should prioritize systematic optimization of the tripartite design through multi-antigen targeting, tissue-specific delivery engineering, and rational combination immunotherapy, aiming to establish mRNA cancer vaccines as a standard-of-care modality.
SN - 2234-943X
ER -